

Supplemental Information

SUPPLEMENTAL REFERENCES

134. Centers for Disease Control and Prevention. Dengue virus infections: 2015 case definition. Available at: <https://www.cdc.gov/nndss/conditions/dengue-virus-infections/case-definition/2015/#:~:text=Clinical%20Description,joint%20pain%2C%20myalgia%2C%20arthralgia>. Accessed April 28, 2021
135. Centers for Disease Control and Prevention. Dengue: clinical presentation. Available at: <https://www.cdc.gov/dengue/healthcare-providers/clinical-presentation.html>. Accessed November 8, 2021
136. Torresi J, Richmond PC, Heron LG, et al. Replication and excretion of the live attenuated tetravalent dengue vaccine CYD-TDV in a flavivirus-naive adult population: assessment of vaccine viremia and virus shedding. *J Infect Dis*. 2017;216(7):834–841
137. Rupp R, Luckasen GJ, Kirstein JL, et al. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study. *Vaccine*. 2015;33(46):6351–6359
138. Russell K, Rupp R, Morales-Ramirez J, et al. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated tetravalent dengue vaccine (V181) in flavivirus-naive and flavivirus-experienced health adults. In: Proceedings from the American Society of Tropical Medicine and Hygiene Annual Meeting; November 20–24, 2019; National Harbor, MD